128 related articles for article (PubMed ID: 37247890)
21. Immunohistochemical expression of CDX2, β-catenin, and TP53 in inflammatory bowel disease-associated colorectal cancer.
Laurent C; Svrcek M; Flejou JF; Chenard MP; Duclos B; Freund JN; Reimund JM
Inflamm Bowel Dis; 2011 Jan; 17(1):232-40. PubMed ID: 20815042
[TBL] [Abstract][Full Text] [Related]
22. CDX2 Protein Expression in Colorectal Cancer and ItsCorrelation with Clinical and Pathological Characteristics, Prognosis, and Survival Rate of Patients.
Asgari-Karchekani S; Karimian M; Mazoochi T; Taheri MA; Khamehchian T
J Gastrointest Cancer; 2020 Sep; 51(3):844-849. PubMed ID: 31630373
[TBL] [Abstract][Full Text] [Related]
23. Expression of homeodomain protein CDX2 in colorectal adenoma and adenocarcinoma.
Bakaris S; Cetinkaya A; Ezberci F; Ekerbicer H
Histol Histopathol; 2008 Sep; 23(9):1043-7. PubMed ID: 18581275
[TBL] [Abstract][Full Text] [Related]
24. The homeobox gene CDX2 in colorectal carcinoma: a genetic analysis.
Sivagnanasundaram S; Islam I; Talbot I; Drummond F; Walters JR; Edwards YH
Br J Cancer; 2001 Jan; 84(2):218-25. PubMed ID: 11161380
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients.
Wong SC; Ng SS; Cheung MT; Luk LY; Chan CM; Cheung AH; Lee VH; Lai PB; Ma BB; Hui EP; Lam MY; Au TC; Chan AT
Br J Cancer; 2011 Mar; 104(6):1000-6. PubMed ID: 21364588
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues.
Zhu AX; Knox JJ
Oncologist; 2012; 17(12):1504-7. PubMed ID: 23220842
[TBL] [Abstract][Full Text] [Related]
27. CDX2-positive breast cancer presented with axillary lymph node metastases: A case report.
Hoshina H; Takei H; Sakatani T; Naito Z
Cancer Treat Res Commun; 2021; 26():100300. PubMed ID: 33421821
[TBL] [Abstract][Full Text] [Related]
28. BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression.
Landau MS; Kuan SF; Chiosea S; Pai RK
Hum Pathol; 2014 Aug; 45(8):1704-12. PubMed ID: 24908142
[TBL] [Abstract][Full Text] [Related]
29. Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
Winn B; Tavares R; Matoso A; Noble L; Fanion J; Waldman SA; Resnick MB
Hum Pathol; 2010 Jan; 41(1):123-8. PubMed ID: 19800103
[TBL] [Abstract][Full Text] [Related]
30. Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis.
Shigematsu Y; Inamura K; Yamamoto N; Mise Y; Saiura A; Ishikawa Y; Takahashi S; Kanda H
BMC Cancer; 2018 Oct; 18(1):980. PubMed ID: 30326864
[TBL] [Abstract][Full Text] [Related]
31. SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary.
Dabir PD; Svanholm H; Christiansen JJ
APMIS; 2018 Jun; 126(6):494-500. PubMed ID: 29924451
[TBL] [Abstract][Full Text] [Related]
32. [Expression of Cdx2 protein in colorectal cancer].
Pack JH; Kim TD; Oh HA; Lee EJ; Kim JW; Jang BI; Kim TN; Jung MK; Bae YK
Korean J Gastroenterol; 2005 Sep; 46(3):204-10. PubMed ID: 16179840
[TBL] [Abstract][Full Text] [Related]
33. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites.
De Lott LB; Morrison C; Suster S; Cohn DE; Frankel WL
Arch Pathol Lab Med; 2005 Sep; 129(9):1100-5. PubMed ID: 16119980
[TBL] [Abstract][Full Text] [Related]
34. Cdx2 as a marker for neuroendocrine tumors of unknown primary sites.
Erickson LA; Papouchado B; Dimashkieh H; Zhang S; Nakamura N; Lloyd RV
Endocr Pathol; 2004; 15(3):247-52. PubMed ID: 15640551
[TBL] [Abstract][Full Text] [Related]
35. LIN28B induces a differentiation program through CDX2 in colon cancer.
Suzuki K; Masuike Y; Mizuno R; Sachdeva UM; Chatterji P; Andres SF; Sun W; Klein-Szanto AJ; Besharati S; Remotti HE; Verzi MP; Rustgi AK
JCI Insight; 2021 May; 6(9):. PubMed ID: 33755595
[TBL] [Abstract][Full Text] [Related]
36. A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of colorectal carcinoma.
Wong NACS; Adamczyk LA; Evans S; Cullen J; Oniscu A; Oien KA
Histopathology; 2017 Jul; 71(1):34-41. PubMed ID: 28226180
[TBL] [Abstract][Full Text] [Related]
37. Association of CDX2 Expression With Survival in Early Colorectal Cancer: A Systematic Review and Meta-analysis.
Tomasello G; Barni S; Turati L; Ghidini M; Pezzica E; Passalacqua R; Petrelli F
Clin Colorectal Cancer; 2018 Jun; 17(2):97-103. PubMed ID: 29519711
[TBL] [Abstract][Full Text] [Related]
38. CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs.
Barbareschi M; Murer B; Colby TV; Chilosi M; Macri E; Loda M; Doglioni C
Am J Surg Pathol; 2003 Feb; 27(2):141-9. PubMed ID: 12548159
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7.
Vang R; Gown AM; Wu LS; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Ronnett BM
Mod Pathol; 2006 Nov; 19(11):1421-8. PubMed ID: 16980943
[TBL] [Abstract][Full Text] [Related]
40. Utility of tissue-specific transcription factors thyroid transcription factor 1 and Cdx2 in determining the primary site of metastatic adenocarcinomas to the brain.
Strickland-Marmol LB; Khoor A; Livingston SK; Rojiani A
Arch Pathol Lab Med; 2007 Nov; 131(11):1686-90. PubMed ID: 17979487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
